Long Term Open Label Study in Narcolepsy With BF2.649 (Pitolisant)

Summary

This is a multicentric International Phase III,Long term open label study(12 months)assessing the long-term safety and efficacy of BF2.649 (Pitolisant)in the treatment of Excessive Daytime Sleepiness (EDS) in narcoleptic patients with or without cataplexy.

Timeline

Start

2011-05

Primary completion

2013-10

Completion

2016-09

Drugs

Indications